Erlotinib-responsive actinic keratoses

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 581-584

  Hermanns, Jean Francois ^a   Piérard, Gerald E ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Actinic keratoses; Erlotinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CASE REPORT; DRUG ANTAGONISM; HUMAN; INFLAMMATION; KERATOSIS; MALE; SCINTISCANNING; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; SUNLIGHT;

CARCINOMA, SQUAMOUS CELL; HUMANS; INFLAMMATION; KERATOSIS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; SUNLIGHT;

EID: 38449098014     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.581     Document Type: Review

References (29)

1. Bunn JPA and Franklin W: Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 29: 38-44, 2002.
2. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748, 1999. (Pubitemid 29503548)
3. Pérez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238-3247, 2004. (Pubitemid 41103678)
4. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3: 599-606, 2005. (Pubitemid 41647826)
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 253: 123-132, 2005. (Pubitemid 41058344)
6. Tang PA, Tsao MS and Moore MJ: A review of erlotinib and its clinical use. Expert Opin Pharmacother 7: 177-193, 2006. (Pubitemid 43263257)
7. Catania C, De Pas TM, Pelosi G, Manzotti M, Adamoli L, Nole P and Goldhirsch A: Erlotinib-induced breast cancer regression. Ann Pharmacother 40: 2043-2047, 1006.
8. Wyatt JA, Leonard GD and Sachs DL: Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 7: 45-63, 2006.
9. Segaert S and Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16: 1425-1433, 2005. (Pubitemid 41222414)
10. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P and Halpern AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55: 657-670, 2006. (Pubitemid 44436627)
11. Piérard-Franchimont C, Blaise G, Paquet P, et al: Paroxysmal iatrogenic acne and the epidermal growth factor receptor inhibitors. Rev Med Liège 62: 11-14, 2007. (Pubitemid 351448368)
12. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ and Stadler WM: Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 31: 783-785, 2006. (Pubitemid 44563396)
13. Czarnecki D, Meehan CJ, Bruce F and Culjak G: The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 6: 207-209, 2002. (Pubitemid 34839927)
14. Ehrig T, Cockerell C, Piacquadio D and Dromgoole S: Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg 32: 1261-1265, 2006. (Pubitemid 44569998)
15. Quaedvlieg PJ, Tirsi E, Thissen MR and Krekels GA: Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16: 335-339, 2006. (Pubitemid 44328971)
16. Uhoda I, Quatresooz P, Fumal I, Nikkels AF, Piérard-Franchimont C and Piérard GE: Updating trends in cutaneous cancers in southeast Belgium. Oncol Rep 12: 111-114, 2004.
17. Atkins D, Bang RH, Sternberg MR and Chen SC: Reliable methods to evaluate the burden of actinic keratoses. J Invest Dermatol 126: 591-594, 2006. (Pubitemid 43255646)
18. Jeffes EW and Tang EH: Actinic keratosis. Current treatment options. Am J Clin Dermatol 1: 167-179, 2000.
19. Gupta AK, Davey V and Mcphail H: Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 9: 209-214, 2005. (Pubitemid 44265792)
20. Quatresooz P and Piérard GE: Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol 28: S27-S29, 2003.
21. Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB and Halliday GM: Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 154: 72-78, 2006. (Pubitemid 43381323)
22. Berhane T, Halliday GM, Cooke B and Barnetson RS: Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 146: 810-815, 2002. (Pubitemid 34539190)
23. Susser WS, Whitaker-Worth DL and Grand-Kels JM: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40: 367-398, 1999. (Pubitemid 29115299)
24. Higa GM, Kovach RF and Abraham J: Actinic keratosis and capecitabine therapy. J Oncol Pharm Pract 11: 151-153, 2005.
25. Mittelbronn MA, Mullins DL, Ramos-Caro FA and Flowers FP: Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 37: 677-681, 1998. (Pubitemid 28428318)
26. Cockerell CJ: Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 42: 11-17, 2000.
27. Hurt MA: The nature of solar (actinic) keratosis. Br J Dermatol 156: 408-409, 2007.
28. Perez-Soler R: Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 11: 23-28, 2003.
29. Mohamed MK, Ramalingam S, Lin Y, Goodoing W and Belani CP: Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small-cell lung cancer. Ann Oncol 16: 780-785, 2005. (Pubitemid 40767100)